Treatment of Endometrial Carcinoma



Nearly one century has passed since Thomas Cullen, in his book Cancer of the Uterus published in 1900, described the treatment of endometrial carcinoma with abdominal hysterectomy and bilateral salpingo-oophorectomy and recommended vaginal hysterectomy only in the very obese or medically indigent patients. In the 1920s, Healy was one of the first to study the effects of radiation alone and in combination with surgery in the treatment of endometrial carcinoma. It confirmed that poorly differentiated carcinoma was more difficult to be treated successfully. In 1936, Arneson compared radiation plus surgery with surgery and radiation alone and found that the combination of radiation, followed 3–6 weeks later by hysterectomy was the best method to treat cancer of the corpus uteri and yielded improved 5-year survival. In 1941 Heyman developed a technique of packing the uterus with multiple capsules of radium prior to hysterectomy and showed approximately 60% 5-year survivals in stage I patients.


Endometrial Cancer Obstet Gynecol Endometrial Carcinoma Radical Hysterectomy Myometrial Invasion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aalders JG, Abeler V, Kolstad P (1984) Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 17:85–103PubMedGoogle Scholar
  2. Anderson DG (1965) Management of advanced endometrial adenocarcinoma with medroxyprogesterone acetate. Am J Obstet Gynecol 92:87–97PubMedGoogle Scholar
  3. Anderson DG (1972) The possible mechanisms of action of progestins on endometrial adenocarcinoma. Am J Obstet Gynecol 113:195–211PubMedGoogle Scholar
  4. Annegers J, Malkasian G (1981) Patterns of other neoplasia in patients with endometrial carcinoma. Cancer 48:856–859PubMedGoogle Scholar
  5. Arneson A (1936) Clinical results and histologic changes following the radiation treatment of cancer of the corpus uteri. Am J Roentgenol 36:461Google Scholar
  6. Ayoub J, Audet-Lapointe P, Methot Y et al. (1986) Randomized trial of the addition of cyclical hormonal therapy to combination chemotherapy for advanced endometrial cancer. Gynecol Oncol 23:255Google Scholar
  7. Badib AO, Kurohara SS, Vongtama VY, Webster JH (1969) Evaluation of primary radiation therapy in stage I, group 2 endometrial carcinoma. Radiology 93:417–421PubMedGoogle Scholar
  8. Barni S, Novelli GC, Zanoio L et al. (1981) Chromatin analysis in human endometrial adenocarcinoma before and after treatment with MPA. Virchows Arch (Cell Pathol) 37:167–177Google Scholar
  9. Beck RP, Latour JPA (1963) Necropsy reports on 36 cases of endometrial carcinoma. Am J Obstet Gynecol 85:307–311PubMedGoogle Scholar
  10. Beiler DD, Schmutz DA, O’Rourke TL (1972) Carcinoma of the endometrium: radiation and surgery versus surgery alone. Radiology 102:159–164PubMedGoogle Scholar
  11. Berman ML, Barlow SC, Lagasse LD et al. (1980) Prognosis and treatment of endometrial cancer. Am J Obstet Gynecol 136:679–688PubMedGoogle Scholar
  12. Berman ML, Afridi MA, Kanbour AL, Ball HG (1982) Risk factors and prognosis in stage II endometrial cancer. Gynecol Oncol 14:49–61PubMedGoogle Scholar
  13. Binart N, Mester J, Baulier EE, Catelli MG (1982) Combined effects of progesterone and Tamoxifen in the chick oviduct. Endocrinology 111:7–16PubMedGoogle Scholar
  14. Bojar H, Stusckhe M, Staib W (1983) Effects of high-dose medroxyprogesterone acetate (MPA) on plasma membrane lipid mobility. J Steroid Biochem [Suppl] 19:107Google Scholar
  15. Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS (1981) Adjuvant hormone therapy of primary endometrial carcinoma with oxyprogesterone caproate. Gynecol Oncol 11:371–378PubMedGoogle Scholar
  16. Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS (1985) Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol 20:139–155PubMedGoogle Scholar
  17. Bonte J, Kohorn I (1978) The response of hyperplastic, dysplastic and neoplastic endometrium to progestational therapy. In: Richardson GS, MacLaughlin DT (eds) Hormone biology of endometrial cancer. UICC, Geneva, p 155–184Google Scholar
  18. Bonte J (1979) Developments in endocrine therapy of endometrial and ovarian cancer. Rev Endocrin Relat Cancer 3:11–17Google Scholar
  19. Bonte J (1980) Hormonal dependence of endometrial adenocarcinoma and its hormonal sensitivity to progesterone and antiestrogens. Prog Cancer Res Ther 14:443–455Google Scholar
  20. Bonte J, Ide P, Billiet G, Wynants P (1981) Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol 11:140–161PubMedGoogle Scholar
  21. Bonte J (1983) Hormone dependency and hormone responsiveness of endometrial adenocarcinoma to estrogens, progesterone and antiestrogens. In: Campio L, Robustelli G, Cuna D, Taylor RW (eds) Role of medroxyprogesterone in endocrine-related tumors, vol II. Raven, New York, p 141–156Google Scholar
  22. Bonte J (1984) The endometrial adenocarcinoma as a model for hormone-dependency and hormone-responsiveness of gynaecological cancers. Eur J Obstet Gynecol Reprod Biol 18:335–341PubMedGoogle Scholar
  23. Bonte J (1985) Hormone treatment of gynecological tumors. In: Williams CJ, White-house JMA (eds) Cancer investigation and management, vol 3: cancer of the female reproductive system. Wiley, New York, p 141Google Scholar
  24. Boronow RC (1969) Carcinoma of the corpus: treatment at MD Anderson Hospital, in cancer of the uterus and ovary (Anderson Hospital). Year Book Medical Publishers, Chicago, p 35–61Google Scholar
  25. Boronow RC, Morrow CP, Creasman WT et al. (1984) Surgical staging of endometrial cancer: 1. Clinical-pathologic findings of a prospective study. Obstet Gynecol 63:825–838PubMedGoogle Scholar
  26. Broens J, Mouridsen HT, Soerensen HM (1980) Tamoxifen in advanced endometrial carcinoma. Cancer Chemother Pharmacol 4:213PubMedGoogle Scholar
  27. Bruckner HW, Deppe G (1977) Combination chemotherapy of advanced endometrial carcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. Obstet Gynecol 50:10–125Google Scholar
  28. Brunschwig A, Murphy AI (1954) The rationale for radical panhysterectomy and pelvic node excision in carcinoma of the corpus uteri. Am J Obstet Gynecol 68:1482–1488PubMedGoogle Scholar
  29. Caffier H, Horner G, Baum RJ (1982) Treatment of advanced or recurrent endometrial adenocarcinoma with progestins, including medroxyprogesterone acetate. In: Proceedings of the international symposium on medroxyprogesterone acetate. Excerpta Medica, Geneva, 389–396Google Scholar
  30. Chau PM (1962) Technic and evaluation of preoperative radium therapy in adenocarcinoma of the uterine corpus. In: Carcinoma of the uterine cervix, endometrium and ovary. Year Book Medical Publishers, Chicago, p 235Google Scholar
  31. Christensen C, Malviya V, Deppe G et al. (1985) RL-95: a model for chemotherapeutic agents in endometrial adenocarcinoma. Gynecol Oncol 20:266Google Scholar
  32. Cohen CJ, Bruckner HW, Deppe G et al. (1984) Multidrug treatment of advanced and recurrent endometrial carcinoma: a gynecologic oncology group study. Obstet Gynecol 63:719–726PubMedGoogle Scholar
  33. Connelly PJ, Alberhasky RC, Christopherson WM (1982) Carcinoma of the endometrium III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 59:569–575PubMedGoogle Scholar
  34. Creasman WT, Rutledge FN (1971) The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol 110:773–781PubMedGoogle Scholar
  35. Creasman WT, Weed JC Jr (1981) Carcinoma of endometrium (FIGO Stage I and II): clinical features and management. In: Coppleson M (ed) Gynecologic oncology, fundamental principles and clinical practice. Churchill Livingstone, Edinbourgh, p 571–577Google Scholar
  36. Creasman WT, Boronow RC, Morrow CP et al. (1976) Adenocarcinoma of the endometrium: its metastatic, lymph node potential. Gynecol Oncol 4:239–243PubMedGoogle Scholar
  37. Creasman WT, DiSaia PJ, Blessing T et al. (1981) Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol 141:921–929PubMedGoogle Scholar
  38. Creasman WT, Henderson D, Clarke-Pearson DL (1984) Use of estrogen after treatment for adenocarcinoma of the endometrium. Gynecol Oncol 17:255Google Scholar
  39. Cullen TH (1900) Cancer of the uterus. Philadelphia, Saunders.Google Scholar
  40. Dahle R (1956) Transtubal spread of tumor cells in carcinoma of the body of the uterus. Surg Gynecol Obstet 102:332Google Scholar
  41. Delclos L, Braun EJ, Herrera JR et al. (1963) Whole abdominal irradiation by cobalt-60 moving-step technic. Radiology 81:632–641PubMedGoogle Scholar
  42. Delclos L, Fletcher GH (1969) Malignant tumors of the endometrium: evaluation of some aspects of radiotherapy, M. D. Anderson Hospital. In: Cancer of the uterus and ovary 11th clinical conference on cancer, M. D. Anderson Hospital and Tumor Institute, Houston, 1966. Year Book Medical Publishers, Chicago, p 62–72Google Scholar
  43. Dembo AJ, Van Dyk J, Japp B et al. (1979) Whole abdominal irradiation by a moving-strip technique for patients with ovarian cancer. Int J Radiat Oncol Biol Phys 5:1933–1942PubMedGoogle Scholar
  44. Deppe G (1982) Chemotherapeutic treatment of endometrial carcinoma. Clin Obstet Gynaecol 25:93–99Google Scholar
  45. Devita VT, Wasserman TH, Young RC, Carter SK (1976) Perspectives on research in gynecologic oncology. Cancer 38:509–525PubMedGoogle Scholar
  46. Dobbie BMW (1953) Vaginal recurrences in carcinoma of the body of the uterus and their prevention by radium therapy. J Obstet Gynecol Br Commonw 60:702–705Google Scholar
  47. Du Toit JP (1985) Carcinoma of the uterine body. In: Shepherd JH, Monaghan JM (eds) Clinical gynecological oncology. Blackwell, Oxford, p 97–132Google Scholar
  48. Enk L, Crona N, Friberg LG et al. (1985) High-dose depot-medroxyprogesterone acetate - effects on the fatty acid composition of serum lecithin and cholesterol ester. Gynecol Oncol 22:317–323PubMedGoogle Scholar
  49. Ferenczy A (1977) Surface ultrastructural response of the human uterine lining epithelium to homonal environment. A scanning electron microscopic study. Acta Cytol 21:566–572PubMedGoogle Scholar
  50. Ferrazzi E, Cartei G, Mattazazzo R, Fiorentino M (1977) Oestrogen-like effect of tamoxifen on vaginal epithelium (letter). Br Med J 1:1351–1352PubMedGoogle Scholar
  51. FIGO (1985) Annual report on the results of the treatment in gynecological cancer, vol 18. Statements of results obtained in 1973–1975. Radium hemmet, StockholmGoogle Scholar
  52. Frick HC, Munnell EW, Richart RM et al. (1973) Carcinoma of endometrium. Am J Obstet Gynecol 115:663–676PubMedGoogle Scholar
  53. Gagnon JD, Moss WT, Gabourel LS, Stevens KR (1979) External irradiation in the management of stage II endometrial carcinoma. Cancer 44:1247–1251PubMedGoogle Scholar
  54. Geisler HE (1973) The use of megestrol acetate in the treatment of advanced malignant lesions of the endometrium. Gynecol Oncol 1:340Google Scholar
  55. Graham J (1971) The value of preoperative or postoperative treatment by radium for carcinoma of the uterine body. Surg Gynecol Obstet 132:855–860PubMedGoogle Scholar
  56. Gravanis A, Binart P, Robel P et al. (1984) Estrogen-like effects of combined dexametha-sone and tamoxifen in the chick oviduct. Biochem Biophys Res Commun 124:57–62PubMedGoogle Scholar
  57. Groom GV, Griffiths K (1976) Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70:421–428PubMedGoogle Scholar
  58. Gurpide E, Tseng L (1977) Estrogen metabolism in normal and neoplastic endometrium. Am J Obstet Gynecol 129:809–816PubMedGoogle Scholar
  59. Gurpide E (1979) Hormonal aspects of carcinoma of the endometrium. Gynecol Cancer 8:191–198Google Scholar
  60. Gurpide E (1981) Hormone receptors in endometrial cancer. Cancer 48:638–641PubMedGoogle Scholar
  61. Gusberg SB, Yannopoulos D (1964) Therapeutic decision in corpus cancer. Am J Obstet Gynecol 88:157–162PubMedGoogle Scholar
  62. Hald I (1981) The use of tamoxifen (‘Novadex’) in endometrial cancer. Rev Endocrin Relat Cancer [Suppl] 8:9–15Google Scholar
  63. Healy WP (1939) Experience with surgical radiation therapy in carcinoma of the corpus uteri. Am J Obstet Gynecol 38:1Google Scholar
  64. Henriksen E (1949) The lymphatic spread of carcinoma of the cervix and of the body of the uterus; a study of 420 necropsies. Am J Obstet Gynecol 58:924–940PubMedGoogle Scholar
  65. Heyman J (1947) Improvement of results in the treatment of uterine cancer. J Am Hosp Ass 135:412–416Google Scholar
  66. Heyman J, Reuterwall O, Beuner S (1941) The Radiumhemmet experience with radiotherapy in cancer of the corpus of the uterus: classification, method of treatment and results. Acta Radiol 22:11–98Google Scholar
  67. Holincka CF, Gurpide E (1980) Peroxidase activity in glands and stroma of human endometrium. Am J Obstet Gynecol 138:599–603Google Scholar
  68. Horton J, Bezz CB, Arsenean J et al. (1978) Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 62:154–161Google Scholar
  69. Iacobelli S, Sica G, Natoli C, Gatti D (1983) Inhibitory effects of medroxyprogesterone acetate on the proliferation of human breast cancer cells. In: Campio L, Robustelli G, Cuna D, Taylor RW (eds) Role of medroxyprogesterone in endocrine-related tumors, vol 2. Raven, New York, p 1–6Google Scholar
  70. Ishiwata I, Nozawa S, Okumura H (1977) Effects of 17β-estradiol and progesterone on growth and morphology of human endometrial carcinoma cells in vitro. Cancer Res 37:4246–4249PubMedGoogle Scholar
  71. Janne O (1979) Female sex steroid receptors in normal hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration. Int J Cancer 24:545–554PubMedGoogle Scholar
  72. Jones HW (1975) Treatment of adenocarcinoma of the endometrium. Obstet Gynecol Surv 30:147–169PubMedGoogle Scholar
  73. Jordan VC, Dix CJ (1978) Effect of estradiol benzoate, tamoxifen and monohydroxy-tamoxifen on immature rat uterine progesterone receptor synthesis and endometrial cell division. J Steroid Biochem 11:285–291Google Scholar
  74. Joslin CAF (1985) The place for radiotherapy in endometrial cancer. Proceedings of International Meeting of Gynaecological Oncology, Venice-Lido (Italy) Apr 1985, p21–24Google Scholar
  75. Joslin CAF, Vaishampayan GV, Mallik T (1977) The treatment of early cancer of the corpus uteri. Radiology 50:38–45Google Scholar
  76. Kadar NRD, Kohom EI, LiVolsi VA, Kapp DS (1982) Histologic variants of cervical involvement by endometrial carcinoma. Obstet Gynecol 59:85–92PubMedGoogle Scholar
  77. Kauppila A, Fribert LG (1981) Hormone and cytotoxic chemotherapy for endometrial carcinoma. Acta Obstet Gynecol Scand [Suppl] 101:59–64Google Scholar
  78. Kauppila A, Gronroos M, Niemineu U (1982) Clinical outcome of endometrial cancer. Obstet Gynecol 60:473–480PubMedGoogle Scholar
  79. Keettel WC, Pixley EE, Buchsbaum HJ (1974) Experience with peritoneal cytology in the management of gynecological malignancies. Am J Obstet Gynecol 120:174–182PubMedGoogle Scholar
  80. Kelley RM (1951) Proceedings of the second conference on steroids and cancer, Council on Pharmacy and Chemistry, American Medical Association Chicago, 116Google Scholar
  81. Kelley RM, Baker WH (1961) Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 264:216–222PubMedGoogle Scholar
  82. Kennedy A, Peterson G, Becker S, Webster K (1986) Experience with pelvic washings in stage I and II endometrial adenocarcinoma. Gynecol Oncol 23:256Google Scholar
  83. Kinsella TJ, Bloomer WD, Lavin PT et al. (1980) Stage II endometrial carcinoma: ten year follow up combined radiation and surgical treatment. Gynecol Oncol 11:290–297Google Scholar
  84. Kistner RW, Griffiths CT, Craig JM (1965) Use of progestational agents in the management of endometrial cancer. Cancer 18:1563–1579PubMedGoogle Scholar
  85. Kjellgren O, Magnusson SS (1970) Efficacy of primary radiation in carcinoma of the endometrium. Acta Radiol 9:102–104Google Scholar
  86. Kohorn El (1976) Gestagens and endometrial carcinoma. Gynecol Oncol 4:398–411PubMedGoogle Scholar
  87. Lampe I (1963) Endometrial carcinoma. Am J Roentgenol 90:1011–1015Google Scholar
  88. Laatikainen T, Nieminea U, Adlercreutz H (1979) Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma. Acta Obstet Gynecol Scand 58:85–99Google Scholar
  89. Lewis B, Stallworthy JA, Cowdell R (1970) Adenocarcinoma of the body of the uterus. J Obstet Gynecol Br Commonw 77:343–348Google Scholar
  90. Lewis GC, Slack NH et al. (1974) Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 2:368–376PubMedGoogle Scholar
  91. Li SY (1988) Treatment. In: Li SY (ed) Endometrial carcinoma. People’s Medical Publishing House, Beijing, p 94–168Google Scholar
  92. Lloyd RE, Jones SE, Sammon SE (1975) Southwest oncology group members: “Phase II trial of adriamycin and cyclophosphamide: a southwest oncology group pilot study”. Proc Am Assoc Cancer Res 16:265Google Scholar
  93. Lovecchio JL, Averette HE, Lichtinger M et al. (1984) Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-platinum and megestrol acetate. Obstet Gynecol 63:557–560PubMedGoogle Scholar
  94. Malkasian GD, Decker DG, Mussey E, Johnson CG (1971) Progestin treatment of recurrent endometrial carcinoma. Am J Obstet Gynecol 110:15–23PubMedGoogle Scholar
  95. Marchesoni D, Mozzanega B, Gangemi M, Enrichi H (1980) Tamoxifen in the therapy of post-menopausal endometrial cancer: variations in some hormonal parameters. Eur J Gynaecol Oncol 1:116–121PubMedGoogle Scholar
  96. Marcial VA, Tome JM, Ubinas J (1969) The combination of external irradiation and curietherapy used preoperatively in adenocarcinoma of the endometrium. Am J Roentgenol Nucl Med 105:586–595Google Scholar
  97. Martin PM, Rolland PH, Jacquemier J et al. (1979) Multiple steroid receptors in human breast cancer. II. Estrogen and progesterone receptors in 672 primary tumors. III. Relationship between steroid receptors and the state of differentiation and the activity of carcinomas throughout the pathologic feature. Cancer Chemother Pharmacol 2:107–120PubMedGoogle Scholar
  98. Masson JC, Gregg RD (1940) Carcinoma of the body of the uterus: experience of the Mayo Clinic for 24 years. Surg Gynecol Obstet 70:1083Google Scholar
  99. McCabe JG, Sagerman RH (1979) Treatment of endometrial cancer in a regional radiation therapy center. Cancer 43:1052–1057PubMedGoogle Scholar
  100. McGrew EA, Laws JF, Coles WH (1954) Free malignant cells in relation to recurrence of carcinoma of the colon. JAMA 154:1251Google Scholar
  101. Milton PJD, Metters JS (1972) Endometrial carcinoma - an analysis of 355 patients treated at St. Thomas’ Hospital, 1945–1969. J Obstet Gynecol Br Commonw 79:455–464Google Scholar
  102. Moazzami B, Van der Walt JD, Boyd NR (1983) Use of progestogens as an adjuvant to surgery in the treatment of stage I adenocarcinoma of the uterine corpus. Br J Obstet Gynaecol 90:178–181PubMedGoogle Scholar
  103. Morrow CP, DiSaia PJ, Townsend DE (1973) Current management of endometrial carcinoma. Obstet Gynecol 42:399–406PubMedGoogle Scholar
  104. Morrow CP, Townsend DE (1981) Cancer of the uterine corpus. In: Synopsis of gynecologic oncology. Wiley, New York, p 133Google Scholar
  105. Morrow CP, Schlaerth JB (1982) Surgical management of endometrial carcinoma. Clin Obstet Gynecol 25:81–92PubMedGoogle Scholar
  106. Morrow CP, Creasman WT, Homesley H et al. (1986) Recurrence in endometrial carcinoma as a function of extended surgical staging data (a gynecological oncology group study). In: Morrow CP, Smart Ge (eds) Gynecological oncology. Springer Berlin Heidelberg New York, p 147–153Google Scholar
  107. Mortel R, Levy C, Welff JP et al. (1981) Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen. Cancer 41:1140–1147Google Scholar
  108. Mortel R, Zaino R, Satyaswaroop PG (1984) Response of endometrial carcinoma to sequential treatment with tamoxifen and progestin in the Nude Mouse Model. Gynecol Oncol 17:253–254Google Scholar
  109. Mortel R, Zaino RJ, Satyaswaroop PG (1985) Response of human endometrial carcinoma to various doses of estradiol and tamoxifen in the nude mouse model. Gynecol Oncol 20:257Google Scholar
  110. Muggia FM, Chia GA, Reed LJ, Romney SL (1977) Doxorubicin-cyclophosphamide: effective therapy for advanced endometrial cancer. Am J Obstet Gynecol 128:314–319PubMedGoogle Scholar
  111. Nahhas WA, Whitney CW, Stryker JA et al. (1980) Stage II endometrial carcinoma. Gynecol Oncol 10:303–311PubMedGoogle Scholar
  112. Nahhas WA, Zaino R, Mortel R (1984) Residual carcinoma in the surgical specimen of patients with endometrial adenocarcinoma undergoing preoperative radiation therapy. A study of 80 patients and a literature review. Gynecol Oncol 18:165–176PubMedGoogle Scholar
  113. Onsrud M, Kolstad P, Normann T (1976) Postoperative external pelvic irradiation in carcinoma of the corpus stage I: a controlled clinical trial. Gynecol Oncol 4:222–231PubMedGoogle Scholar
  114. Pannutti F (1981) High doses of medroxyprogesterone acetate in advanced cancer treatment. Plasma levels and bioavailability after single and multiple dose administration, preliminary results. In symposium: role of medroxyprogesterone acetate in endocrine-related tumors, 1981 Rome.Google Scholar
  115. Park R, Patow W, Petty W, Zimmermann E (1974) Treatment of adenocarcinoma of the endometrium. Gynecol Oncol 2:60–70PubMedGoogle Scholar
  116. Paterson R (1948) The treatment of malignant disease by radium and X-rays: being a practice of radiotherapy. Arnold, London p 249–432Google Scholar
  117. Piver MS, Yazigi R, Blumenson LE, Tsukada Y (1979) A prospective trial comparing hysterectomy, hysterectomy plus vaginal radium, and uterine radium plus hysterectomy in stage I endometrial carcinoma. Obstet Gynecol 54:85–89PubMedGoogle Scholar
  118. Piver MS (1980) Stage I endometrial carcinoma: the role of adjunctive radiation therapy. Int J Radiat Oncol Biol Phys 6:367–368PubMedGoogle Scholar
  119. Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-provera) Vs hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45:268–272PubMedGoogle Scholar
  120. Piver MS, Lele SB, Barlow JJ et al. (1982) Para-aortic lymph node evaluation in stage I endometrial carcinoma. Obstet Gynecol 59:97–100PubMedGoogle Scholar
  121. Prodi G, Nicoletti G, DeGiovanni C et al. (1980) Multiple steroid hormone receptors in normal and abnormal human endometrium. J Cancer Res Clin Oncol 98:173–183PubMedGoogle Scholar
  122. Quinn MA, Campbell JJ, Murray R, Pepperell RJ (1981) Tamoxi fen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone. Aust NZ J Obstet Gynaecol 21:226–227Google Scholar
  123. Randall JH, Goddard WBA (1956) A study of 531 cases of endometrial carcinoma. Surg Gynecol Obstet 103:221–226PubMedGoogle Scholar
  124. Reel JR (1976) The mode of action of progestagens on endometrial carcinoma. In: Steroid hormone action and cancer, vol 4, W 1 CU 82M. Plenum, New York, p 85–94Google Scholar
  125. Reifenstein EC (1974) The treatment of advanced endometrial cancer with hydroxyprogesterone caproate. Gynecol Oncol 2:377–414PubMedGoogle Scholar
  126. Ritcher N, Lucas WE, Yon JL, Sanford GD (1981) Preoperative whole pelvic external irradiation in stage I endometrial cancer. Cancer 48:58–62PubMedGoogle Scholar
  127. Robel P, Levy C, Bayard F et al. (1979) Estradiol and progesterone receptors in normal and abnormal human endometrium. In: Klopper et al. (eds) Research on steroids, vol VIII. Academic, London, p 77–85Google Scholar
  128. Robel P, Gravanis A, Roger-Jallais L et al. (1986) Receptors, hormones and antihormones in postmenopausal endometrial carcinoma. In: Bolla M, Racinet C, Vrousos C (eds) Endometrial cancers. 5th Cancer Research Workshop, Grenoble 1985. Karger, Basel, p 119–125Google Scholar
  129. Rutledge FN (1974) The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol 2:331–347PubMedGoogle Scholar
  130. Rutledge FN, Tan SK, Fletcher GM (1958) Vaginal metastasis from adenocarcinoma of the corpus uteri. Am J Obstet Gynecol 75:167–174PubMedGoogle Scholar
  131. Sala JM, Del Regato JA (1961) Treatment of carcinoma of the endometrium. Radiology 79:12–17Google Scholar
  132. Salazar OM, Feldstein ML, DePapp EW et al. (1978) The management of clinical stage I endometrial carcinoma. Cancer 41:1016–1026PubMedGoogle Scholar
  133. Salimtschik M, Mouridsen HT, Loeber J, Johansson E (1980) Comparative pharmacokinetics of MPA administered by oral and i.m. route. Cancer Chemother Pharmacol 4:267–269PubMedGoogle Scholar
  134. Sall S, Sonnenblick B, Stone ML (1970) Factors affecting survival of patients with endometrial adenocarcinoma. Am J Obstet Gynecol 107:116–123PubMedGoogle Scholar
  135. Sall S, DiSaia P, Morrow CP et al. (1979) A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Am J Obstet Gynecol 135:647–650PubMedGoogle Scholar
  136. Satyaswaroop PG, Frost A, Gurpide E (1980) Metabolism and effects of progesterone in the human endometrial adenocarcinoma cell line HEC-1. Steroids 35:21–37PubMedGoogle Scholar
  137. Seski JC, Edwards CL, Herson J et al. (1982) Cisplatin chemotherapy in disseminated endometrial cancer. Obstet Gynecol 59:225–228PubMedGoogle Scholar
  138. Shimm DS, Wang CC, Fuller AF et al. (1986) Management of high-grade stage I adenocarcinoma of the endometrium: hysterectomy following low dose external beam pelvic irradiation. Gynecol Oncol 23:183–191PubMedGoogle Scholar
  139. Silverberg SG, DeGiorgi LS (1974) Histopathologic analysis of preoperative radiation therapy in endometrial carcinoma. Am J Obstet Gynecol 119:698–704PubMedGoogle Scholar
  140. Smith JP, Rutledge F, Soffar SW (1966) Progestins in the treatment of patients with endometrial adenocarcinoma. Am J Obstet Gynecol 94:977–984PubMedGoogle Scholar
  141. Strickland P (1965) Carcinoma corporis uteri: a radical intracavitary treatment. Clin Radiol 16:112–118PubMedGoogle Scholar
  142. Suit HD, Shalek RJ (1963) Response of anoxic C3H mouse mammary carcinoma isotransplants (1–25 mm3) to X irradiation. JNCI 31:479–495PubMedGoogle Scholar
  143. Suit HD, Gallager HS (1964) Intact tumor cells in irradiated tissue. Arch Pathol 78:648–651PubMedGoogle Scholar
  144. Surwit EA, Joelsson I, Einhorn N (1981) Adjunctive radiation therapy in the management of stage I cancer of the endometrium. Obstet Gynecol 58:590–595PubMedGoogle Scholar
  145. Sutherland RL, Mester J, Baulieu EE (1977) Tamoxifen is a potent pure antiestrogen in chick oviduct. Nature 267:434–435PubMedGoogle Scholar
  146. Swenerton KD, Shaw D, White GW, Boyes DA (1979) Treatment of advanced endometrial carcinoma with tamoxifen. N Engl J Med 301:105PubMedGoogle Scholar
  147. Swenerton KD (1980) Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 64:805–811PubMedGoogle Scholar
  148. Tamassia V, Battaglia A, Ganzina F et al. (1982) Pharmacokinetic approach to selection of dose schedules for MPA in clinical oncology. Cancer Chemother Pharmacol 8:151–156PubMedGoogle Scholar
  149. Tamassia V (1986) Clinical pharmacokinetics of medroxyprogesterone acetate: relevance for the treatment of breast and endometrial cancer. In: Bolla M, Racinet C, Vrousos C (eds) Endometrial cancers. 5th Cancer Research Workshop, Grenoble 1985. Karger, Basel, p 168–176Google Scholar
  150. Taylor HC Jr, Becker WF (1947) Carcinoma of the corpus uteri: end-results of treatment in 531 cases from 1926–1940. Surg Gynecol Obstet 84:129–139PubMedGoogle Scholar
  151. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA (1979) Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. Cancer Treat Rep 63:21–27PubMedGoogle Scholar
  152. Thigpen JT, Blessing JA, DiSaia P, Ehrlich C (1985) Treatment of advanced or recurrent endometrial carcinoma with medroxyprogesterone acetate (MPA): a gynecologic oncology group study. Gynecol Oncol 20:250Google Scholar
  153. Truskett ID, Constable WC (1968) Management of carcinoma of the corpus uteri. Am J Obstet Gynecol 101:689–694Google Scholar
  154. Tseng L, Gusberg S, Gurpide E (1977) Estradiol receptor and 17-beta-dehydrogenase in normal and abnormal human endometrium. Ann NY Acad Sci 286:190–198PubMedGoogle Scholar
  155. Varga A, Henriksen E. (1965) Histologic observations on the effect of 17-alpha- hydroxyprogesterone-17-N-caproate on endometrial carcinoma. Obstet Gynecol 26:656–664PubMedGoogle Scholar
  156. Vesterinen E, Backas NE, Pesonen K et al. (1981) Effect of medroxyprogesterone acetate on serum levels of LH, FSH, cortisol and estrone in patients with endometrial carcinoma. Arch Gynecol 230:205–211PubMedGoogle Scholar
  157. Vihko R, Jänne O, Kauppila A (1980) Steroid receptors in normal hyperplastic and malignant human endometria. Ann Clin Res 12:208–215PubMedGoogle Scholar
  158. Vongtama V, Kurohara SS, Badib AO, Webster JH (1970) Second primary cancer of endometrial carcinoma. Cancer 26:842–846PubMedGoogle Scholar
  159. Wait RB (1973) Megestrol acetate in the management of advanced endometrial carcinoma. Obstet Gynecol 41:129–136PubMedGoogle Scholar
  160. Wentz WB (1964) Effect of a progestational agent on endometrial hyperplasia and endometrial cancer. Obstet Gynecol 24:370–375PubMedGoogle Scholar
  161. Wentz WB (1974) Progestin therapy in endometrial hyperplasia. Gynecol Oncol 2:362–367PubMedGoogle Scholar
  162. Wharam MD, Phillips TL, Bagshaw MA (1976) Role of radiation therapy in clinical stage I carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 1:1081–1089PubMedGoogle Scholar
  163. Wintz H (1941) Ergebnisse der Behandlug von Unterleibkrebsen mit Rontgenstrahlen, Strahlentherapie 69:3Google Scholar
  164. Yasizi R, Piver MS, Blumenson L (1983) Malignant peritoneal cytology as prognostic indicator in stage I endometrial cancer. Obstet Gynecol 62:359–362Google Scholar

Copyright information

© The People’s Medical Publishing House Beijing and Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  1. 1.Gynecologic Oncology DepartmentCancer Institute (Hospital) Chinese Academy of Medical SciencesBeijingP.R.China

Personalised recommendations